Bionano Genomics, Inc. (BNGO)
Nasdaq · Healthcare · Medical Instruments & Supplies
$1.45−2.36%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $17.0M
- 52-week range
- $1.00 – $2.23
- 52-week change
- −26.37%
- EPS (trailing)
- −$3.02
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $28.5M (−7.37%)
- Net income
- −$26.4M
- Operating margin
- −116.9%
- Diluted EPS
- −$4.85
From the company’s annual report on SEC EDGAR.
About Bionano Genomics, Inc.
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules.
Headquarters: San Diego, United States · 95 employees · bionano.com